Skip to content
Subscriber Only

Fosun's $1.5 Billion Biotech Arm Mulls Hong Kong IPO

  • Billionaire-backed drug developer may test proposed new rules
  • Henlius Biotech’s offering could raise at least $500 million
Updated on

Shanghai Henlius Biotech Inc., backed by Fosun Group, is planning an initial public offering that could make it one of the first to take advantage of proposed Hong Kong listing rules aimed at attracting early-stage drug developers, people familiar with the matter said.

The subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. is considering selling shares in Hong Kong as soon as the second half of this year, according to the people. The offering could raise at least $500 million, one of the people said, asking not to be identified because the information is private.